Quant Healthcare Fund
Direct · GrowthAI Summary
The Quant Healthcare Fund has delivered a 1-year XIRR of 16.24%, outperforming the category average of 14.1% and significantly beating the NIFTY 50's negative return of -2.9% over the same period. Over 3 years, the fund's XIRR of 14.59% lags the category average of 16.82%, but its 3-year rolling return of 21.31% and 3-year CAGR of 22.18% versus the benchmark's 7.75% indicate strong long-term performance. The fund has consistently generated positive alpha across all time horizons, with alpha declining from 21.53% (1Y) to 2.11% (15Y).
The fund exhibits moderate volatility with a beta of approximately 0.82 against the NIFTY 50, indicating lower sensitivity to market movements. Its maximum drawdown is -25.21%, with a recovery period of 487 days, and it has experienced two drawdown events exceeding 10%, suggesting meaningful downside risk. The Calmar ratio of 0.85 over 3 years indicates reasonable risk-adjusted returns, but the drawdown duration and recovery time highlight potential volatility in sectoral funds.
The fund is highly concentrated in pharmaceuticals and biotechnology, with 46.4% of assets in this sector, and holds only 11 stocks in total. Top holdings include Glaxosmithkline Pharmaceuticals (9.93%), Concord Biotech (9.66%), and Zydus Wellness (9.33%), showing significant single-stock concentration. Diversification is limited, with the top 10 holdings accounting for nearly 73% of the portfolio, and the fund also has exposure to food products, healthcare services, and telecom services.
The fund outperforms its category peers over the 1-year period (16.24% vs 14.1% XIRR) but underperforms over the 3-year period (14.59% vs 16.82% XIRR), indicating inconsistent performance relative to peers. Its rolling returns are strong, with a 3-year mean of 21.31%, but the fund's performance has been volatile, as seen in calendar year returns ranging from -4.8% in 2025 to 30.7% in 2024. The fund's alpha generation has been robust, but it has declined over longer horizons, suggesting a need for careful monitoring.
This fund is suitable for investors with a high risk tolerance and a long-term investment horizon of at least 5-7 years, given the sectoral concentration and potential for significant drawdowns. It is best suited for those seeking exposure to the healthcare and pharmaceutical sector and who can withstand volatility without panic selling. Investors should be aware of the fund's concentration risk and consider it as a satellite holding rather than a core portfolio component.
- Strong 1-year XIRR of 16.24% outperforming the category average by 2.14 percentage points.
- Consistent positive alpha across all time horizons, with a 1-year alpha of 21.53% and 3-year alpha of 14.65%.
- Lower downside capture ratio (67.33% over 1 year) indicates the fund loses less than the benchmark during market declines.
- High concentration in pharmaceuticals (46.4% of portfolio) and only 11 holdings, leading to significant sector and stock-specific risk.
- Underperformance versus category average over 3 years (14.59% vs 16.82% XIRR) and a maximum drawdown of -25.21% with a recovery period of 487 days.
Generated on 30-08-2026, 2:59 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.35 L | 16.2% | -27.4% | 81.9% |
| 3 Years | ₹36.00 L | ₹44.46 L | 14.6% | 11.7% | 17.1% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 16.2% | 14.4% | 14.1% | +1.8% |
| 3 Years | 14.6% | 11.1% | 16.8% | +3.5% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 15.8% | 8.7% | -12.3% | 67.6% | 0.40 | 1.43 | 74% | — | — |
| 3 Years | 21.3% | 21.4% | 20.2% | 22.2% | 28.31 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +21.53 | 0.81 | 96.5% | 67.3% | 20.4% | -2.9% |
| 3 Years | +14.65 | 0.83 | 94.6% | 74.9% | 22.2% | 7.8% |
| 5 Years | +9.20 | 0.82 | 94.9% | 73.0% | 13.7% | 4.0% |
| 7 Years | +6.06 | 0.82 | 94.9% | 73.0% | 9.6% | 2.9% |
| 10 Years | +3.81 | 0.82 | 94.9% | 73.0% | 6.6% | 2.0% |
| 12 Years | +2.95 | 0.82 | 94.9% | 73.0% | 5.5% | 1.7% |
| 15 Years | +2.11 | 0.82 | 94.9% | 73.0% | 4.4% | 1.3% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 9.93% |
| 2 | Concord Biotech Limited | 9.66% |
| 3 | Zydus Wellness Ltd | 9.33% |
| 4 | Aster DM Healthcare Limited | 9.25% |
| 5 | HFCL Limited | 7.89% |
| 6 | SMS Pharmaceuticals Limited | 7.27% |
| 7 | IPCA Laboratories Ltd | 5.93% |
| 8 | Pfizer Ltd | 5.82% |
| 9 | Aurobindo Pharma Limited | 5.14% |
| 10 | Strides Pharma Science Ltd | 2.64% |